Results 221 to 230 of about 97,023 (309)

Impact of Underlying Liver Disease on the Risk and Prognostic Factors of Breast Cancer Liver Metastases: A Retrospective Multicenter Cohort Study

Cancer Medicine, Volume 15, Issue 5, May 2026.
ABSTRACT Objective To examine factors influencing breast cancer liver metastases (BCLM) and assess the impact of underlying liver diseases (nonalcoholic fatty liver and HBsAg infection) on BCLM development. Methods Patients diagnosed with breast cancer at four affiliated hospitals in China between 2014 and 2024 were included.
Xiaowen Wang, Yuan Zhang, Qiwei Yang, Luo Yang, Yanhui Wang, Xiangxin Zeng, Long Zou, Yujuan Guo, Wenyang Zhou, Yuqi Jiang, Jiezhong Wu, Peng Zhang, Song Zhou, Guangjuan Zheng, Tao Huang, Genshu Wang, Kunpeng Hu   +16 more
wiley   +1 more source

An XGBoost‐Based Multicenter Model for Predicting HBV‐Related Hepatocellular Carcinoma: Development and Validation

Cancer Medicine, Volume 15, Issue 5, May 2026.
We developed a web‐based interactive tool to estimate individualized HCC risk in chronic HBV patients, enabling clinicians to input real‐time data for personalized risk probabilities and evidence‐based actionable recommendations. ABSTRACT Background The 5‐year survival rate for hepatocellular carcinoma (HCC) is stage‐dependent, yet existing models lack
Yong Lin, Hai‐Yan Zhuo, Hui‐Wen Song, Li‐Na Zhou, Mei‐Zhu Hong, Chun Lin, Peng‐Fei Guo, Jin‐Shui Pan   +7 more
wiley   +1 more source

Hepatitis Vaccines: Recent Advances and Challenges. [PDF]

Vaccines (Basel)
Lu M, Liu Y, Li L, Liu X, Wu B, Wu Y.
europepmc   +1 more source

Trimethoprim/Sulfamethoxazole‐Induced Systemic Toxic Epidermal Necrolysis Syndrome: A Case Report

Clinical Case Reports, Volume 14, Issue 5, May 2026.
ABSTRACT Trimethoprim/sulfamethoxazole can induce life‐threatening toxic epidermal necrolysis. Early recognition, immediate drug cessation, and multidisciplinary supportive care are critical. Even with aggressive therapy, mortality remains high, and SCORTEN score aids in prognostication.
Qing Wang, Litong Chen, Wen Ye
wiley   +1 more source

Mechanisms and Therapeutic Strategies for HCV/HBV-Associated B-Cell Non-Hodgkin's Lymphomas: A Viewpoint. [PDF]

Oncol Res
Carloni G, Rinaldi M.
europepmc   +1 more source

Rare Manifestation of Sjogren's Syndrome: Renal Tubular Acidosis‐Induced Hypokalemic Paralysis—A Case Report

Clinical Case Reports, Volume 14, Issue 5, May 2026.
ABSTRACT Sjogren's syndrome (SS) is an autoimmune disorder characterized by inflammation of exocrine glands, often presenting with symptoms such as dry eyes and mouth. Although less common, renal involvement can lead to serious complications like hypokalemic paralysis.
Premendra Vimal, Dhiraj Chaurasia, Dipesh Jha, Raj Adhikari   +3 more
wiley   +1 more source

Immortalization of Human Adult Alveolar Epithelial Cells to Study Environmental Exposures of the Distal Lung

Current Protocols, Volume 6, Issue 5, May 2026.
Abstract Alveolar epithelial cell type 1 (AT1) and type 2 (AT2) cells make up the saccular gas exchange units of the lung, called alveoli. Formation of alveoli during lung development accounts for the expansive surface area of the lung, allowing for proper respiration and delivery of oxygen to the body.
Evelyn Tran, Laurence St. Pierre, Diego Velarde, Bianca dal Bó, Juan Ramon Alvarez, Kweku Ofosu‐Asante, Nazarius S. Lamango, Yong Huang, Crystal N. Marconett, Zea Borok, Beiyun Zhou, Ite A. Offringa   +11 more
wiley   +1 more source

Nonclassical MHC‐I Molecules: Emerging Therapeutic Targets in Next‐Generation Immunotherapy [PDF]

MedComm (2020)
Immunotherapies dependent on classical MHC‐I molecules face significant challenges, including extreme polymorphism and frequent downregulation in pathological conditions. This review discusses how nonclassical MHC‐I molecules (HLA‐E, HLA‐F, HLA‐G, CD1, MR1) may potentially circumvent these limitations through restricted genetic diversity, stable ...
He W, McMichael A.
europepmc   +2 more sources

Oral Microbiome Diversity Matters on Nucleos(t)ide Analogue Cessation in Chronic Hepatitis B. [PDF]

J Infect Dis
Ghorbani M, Kvedaraite A, Al-Manei K, Too CB, Cederberg S, Johannessen A, Reikvam DH, Valentini D, Maucourant C, Björkström NK, Aleman S, Sällberg Chen M.   +11 more
europepmc   +1 more source

Efficacy and safety of disitamab vedotin (RC48) combined with camrelizumab and S‐1 for neoadjuvant therapy of locally advanced gastric cancer with HER2‐overexpressing: Preliminary results of a prospective, single‐arm, phase II study

Clinical and Translational Medicine, Volume 16, Issue 5, May 2026.
Neoadjuvant disitamab vedotin combined with camrelizumab and S‐1 achieved high pathological response rates with manageable safety in resectable HER2‐overexpressing gastric and gastroesophageal junction cancer. Longitudinal circulating tumour DNA methylation profiling enabled dynamic monitoring of molecular response during treatment.
Longgang Wang, Bing Liu, Luguang Liu, Liqing Liu, Rong Li, Shumei Han, Xu Sun, Bo Bi, Yuanlin Sun, Dong Sun, Jie Chai   +10 more
wiley   +1 more source